Study Details
Full Title
Randomized Study of ONC-392 plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who Progressed on Androgen Receptor (AR) Pathway Inhibition
Principal Investigator
Andrew
Armstrong
Protocol Number
PRO00113824
NCT ID
NCT05682443
Phase
II
Enrollment Status
Open to Enrollment